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Heidi Beate Bentzen,1,2,8 Emmanuelle Rial-Sebbag,9 Flavio D’Abramo,10 Micha1 Witt,11
Genevie`ve Schamps,12 Visˇnja Katic´,13 Dusanca Krajnovic,14 Working Group 1,15 and Jennifer R. Harris16
Background: There is growing consensus that individual genetic research results that are scientifically robust,
analytically valid, and clinically actionable should be offered to research participants. However, the general
practice in European research projects is that results are usually not provided to research participants for many
reasons. This article reports on the views of European experts and scholars who are members of the European
COST Action CHIP ME IS1303 (Citizen’s Health through public-private Initiatives: Public health, Market and
Ethical perspectives) regarding challenges to the feedback of individual genetic results to research participants
in Europe and potential strategies to address these challenges.
Materials and Methods: A consultation of the COST Action members was conducted through an email survey and
a workshop. The results from the consultation were analyzed following a conventional content analysis approach.
Results: Legal frameworks, professional guidelines, and financial, organizational, and human resources to support the
feedback of results are largely missing in Europe. Necessary steps to facilitate the feedback process include clarifying
legal requirements to the feedback of results, developing harmonized European best practices, promoting interdisci-
plinary and cross-institutional collaboration, designing educational programs and cost-efficient IT-based platforms,
involving research ethics committees, and documenting the health benefits and risks of the feedback process.
Conclusions: Coordinated efforts at pan-European level are needed to enable equitable, scientifically sound,
and socially robust feedback of results to research participants.
Introduction
The question of whether to provide feedback on indi-vidual genetic research results from genome sequencing
to research participants has been discussed for almost two
decades.1 Although the debate is still intense, there is growing
consensus among bioethicists, researchers, and policy makers
that research participants should be provided with at least
some genetic results.2 Research groups and research funders
have recently developed guidelines and recommendations3,4
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that encourage researchers to provide participants with genetic
research results, including secondary findings, which are ana-
lytically valid, clinically significant, and clinically actionable,
that is, offer reliable information about health conditions that can
be medically prevented or treated.3 However, these guidelines
are not completely congruentwith policies recently developed in
Europe for the feedback of genetic results in clinical settings.5,6
This lack of harmonization reflects, in part, differences between
the genome sequencing analyses conducted for clinical care
versus those used in research. Clinical applications are generally
limited to the analysis of specific sets of genes to establish a
diagnosis or determine the best treatment alternatives. In con-
trast, research is often discovery oriented and involves con-
ducting analyses encompassing a broader spectrum of variants
or genome-wide inquiry. Consequently, there is a greater like-
lihood that research will generate incidental or other findings
that cannot be readily interpreted, but, which still require ethical
guidelines regarding how these findings are handled.
With a few recent exceptions,7,8 the current practice in most
European research projects is that individual genetic research
results are not provided to research participants.9 Such practice
is, however, expected to be challenged as an increasing number
of large-scale research projects are planned or have been
launched across Europe, which utilize next-generation se-
quencing technologies, andmost likely will produce individual
research results of potential health utility for research partici-
pants.10,11 Another force impacting the practice surrounding
return-of-results stems from the research participants them-
selves, who are increasingly interested in accessing their ge-
netic research results12,13 and interacting with researchers.14
The development of ethically and socially robust feedback
mechanisms for providing genetic research results to research
participants relies on the identification of potential challenges
that may hinder such feedback in Europe, exploration of in-
tercountry similarities concerning these challenges, and deter-
mination of whether these challenges can be addressed in a
harmonized way. This is particularly relevant given the types of
challenges encountered by several projects located outside of
Europe that have started to provide results to their partici-
pants.15–21 For instance, data from some projects showed that it
was difficult to know whether results could be provided to
research participants when the original informed consent did
not address this possibility.16
Another problem relates to the burden associated with al-
lotting the necessary time and resources needed to implement
a meaningful feedback process when the services of genetic
counselors and clinicians are not available.17,18 Moreover,
projects often did not have the necessary resources to use the
services of laboratories that are accredited to verify the ac-
curacy of the results, and struggled to evaluate the clinical
utility of the results in the absence of reference nomenclatures
establishing the pathogenicity of variants.19,20 Finally, some
projects reported that it was difficult to know which specific
results could be legally provided to participants21 and often
found that research ethics committees were reluctant to sup-
port the feedback process.20
BioSHaRE-EU (Biobank Standardisation and Harmonisation
for Research Excellence in the European Union),22 a collabo-
rative research project funded by the European Commission
Seventh Collaboration Framework (2010–2015), developed
frameworks and tools for the harmonization and standardization
of biobank activities.23 Through its ‘‘Ethics’’ and ‘‘Strategic
Integration, Coordination, and Dissemination’’ work packages,
it interfaced and worked closely with the COST Action CHIP
ME IS1303 (Citizen’s Health through public-private Initiatives:
Public health, Market and Ethical perspectives),24 a European
Union framework, which brings together 95 professionals from
25 European countries with expertise in genetics, medicine,
bioethics, law, psychology, social sciences and humanities, and
informatics. This article reports on results from a consultation
with the COST Action members regarding challenges to the
feedback of individual genetic results to research participants in
Europe and potential ways to address these challenges.
Materials and Methods
Between July and August 2014, the chairs of WG1 (Budin-
Ljøsne and Mascalzoni) conducted an email survey among the
COST Action members consisting of an open-ended ques-
tionnaire to inquire about challenges and practical issues that
may impede the feedback of clinically actionable genetic re-
sults to research participants in their country and to identify
potential steps that could be taken to facilitate such feedback.
The COST Action members were asked, whenever possible,
to coordinate responses within their country. To follow up on
the information provided through the email survey, WG1
convened a 1-day workshop at the University of Coimbra,
Portugal, in October 2014, which included 43 members of the
COST Action from 21 European countries. The workshop was
organized as an open space technology (OST) day,25 an ap-
proach to organizing meetings that enables participants to
openly discuss a specific theme without having to follow a
predefined detailed agenda. The workshop was moderated by
a COST Action member with expertise in leading OST events.
Notes were taken by appointed participants during the
workshop and gathered by theWG1 chairs at the end of the day.
The data from the email survey and the workshop notes were
collated, summarized, and analyzed using a content analysis
approach in an inductive way.26 Three categories emerged from
the data: legal, financial, and organizational/societal issues.
Coding was conducted independently by Budin-Ljøsne and
Mascalzoni and disagreements in abstractions were discussed
with Soini and Machado and resolved by consensus. Interrater
reliability and reflection were maximized through comparing
coding between all the authors.
Results
Nineteen questionnaires were collected, providing infor-
mation from 14 of the 25 COST Action countries (Bosnia and
Herzegovina, Croatia, Czech Republic, Estonia, Finland,
Germany, Greece, Italy, Norway, Poland, Portugal, Serbia,
Slovenia, and United Kingdom). In addition, representatives
from eight countries (Belgium, Denmark, France, Iceland,
Ireland, Malta, The Netherlands, and Sweden) contributed to
the workshop discussions. The COST Action members iden-
tified challenges to the feedback of individual research results
to research participants in Europe, which fall into three broad
categories spanning legal, financial, and organizational/soci-
etal issues as described below and summarized in Table 1.
Challenges to the feedback of individual genetic
results to research participants
Legal challenges. The current legal landscape in Europe
provides a framework for returning results under the Conven-
tion on Human Rights and Biomedicine,27 the accompanying
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Additional Protocol on Biomedical Research,28 and through the
Council of Ministers Recommendation on biological materials
of human origin.29 These legal instruments state that research
participants have a right to know any information collected on
their health. The Additional protocol also outlines a research-
er’s ‘‘duty of care,’’ stating that, ‘‘If research gives rise to
information of relevance to the current or future health or
quality of life of research participants, this information must be
offered to them. That shall be done within a framework of
healthcare or counseling. In communication of such informa-
tion, due care must be taken to protect confidentiality and to
respect any wish of a participant not to receive such informa-
tion.’’28 However, there is still uncertainty about which kind of
information equals relevant health information and what a re-
searcher’s duty of care entails. Furthermore, while many Eu-
ropean countries have ratified the Convention and implemented
it into national legal frameworks, there are still notable ex-
ceptions such as the United Kingdom, Belgium, Sweden, and
Germany, and the number of countries that have ratified the
Additional Protocol on Biomedical Research remains small.
Only a few countries such as Estonia,30 France,31 Finland,32
Italy,33 and Norway34 are known to have national regulations
offering research participants the possibility to access (usually
upon request) their genetic and other results. However, the
modalities of such access remain largely unclear. For instance,
it is uncertain whether access to raw sequences should be
granted to research participants. Furthermore, national legis-
lations often require that research data and clinical patient data
are processed separately, thus potentially hindering the use of
research data for clinical purposes.
Financial challenges. Currently, there is no specific financ-
ing dedicated to support the feedback process. However, such
a process may require additional funding, for instance to
verify the analytical validity of the findings, cover the cost of
genetic counseling, or to pay for the necessary administrative
support to recontact participants. Funding schemes for re-
search normally do not encompass the cost of feedback. Si-
milarly, it is unclear whether healthcare systems are willing to
finance the feedback of genetic results that are not produced in
a clinical setting and do not comply with clinical standards.
Organizational/societal challenges. Lack of professional
guidelines and best practices. Professional guidelines and
best practices for the feedback of results to research partici-
pants are largely missing in Europe, with the exception of a
few countries such as the United Kingdom and Norway.7,35–37
Where guidelines do exist, they are often general and do not
offer guidance regarding the specific genetic variants for
which feedback of results should be provided to participants.
In the absence of clear guidelines, the research participants’
access to their genetic results may be handled on a case-by-
case basis. This may lead to inequitable treatment, for instance
if some projects provide results to their participants, while
other similar projects do not provide results or decide to apply
different criteria for doing so. This may be a particularly sa-
lient issue in multicenter European studies where individuals
participating in the same study, but living in different coun-
tries, may have differential access to their results.
Lack of qualified staff. Providing genetic results to research
participants within a qualified professional framework may be
difficult as there are few genetic counselors and clinical ge-
neticists in Europe, in particular in rural regions. Furthermore,
the qualifications of genetic counselors often vary due to the
lack of standard training requirements. General practitioners
and family doctors, who could potentially contribute in the
feedback process, may not have the necessary education in
genetics or the capacity to perform additional tasks, in par-
ticular in countries where there are too few medical doctors
per inhabitant. Prioritization of national healthcare provisions
also plays a major role here; the workload of professionals is
primarily allocated based on clinical needs.
Insufficient interdisciplinary and cross-institutional col-
laboration. The feedback process normally requires that
professions work together. For instance, researchers and
Table 1. Challenges to the Feedback of Individual Genetic Results to Research Participants
in Europe and Potential Strategies to Address Challenges
Challenges
Legal challenges
Unclear how current provisions in European conventions should be interpreted
European conventions often neither ratified by countries nor implemented in national legislation
When national legislation exists, unclear how it applies in practice
Financial challenges
No specific funding to support the feedback process
Unclear whether healthcare systems are willing to finance the feedback process
Organizational/societal challenges
Lack of professional guidelines and best practices to govern the feedback of results
Lack of qualified staff (e.g., genetic counselors) to feedback results to research participants
Insufficient collaboration between professions to support the feedback process
Lack of awareness among research participants regarding the possibility of feedback
Potential strategies to address challenges
Develop harmonized European guidelines for the feedback of results
Allocate specific funding to the feedback process
Document the health benefits of providing genetic results to research participants
Involve research ethics committees early in the design of the feedback process
Promote interdisciplinary and cross-institutional collaboration, for example, through expert networks
Develop educational programs for healthcare professionals
Explore cost-efficient and IT-based tools (e.g., dynamic consent, web-based feedback)
Discuss the modalities of the feedback process with research participants and the general public
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healthcare professionals may collaborate to validate research
results to a clinical standard or to include results communi-
cation in a healthcare setting procedure. However, such
collaboration is often not well established. While clinicians
leading research projects may be able to use their established
networks to organize such activities, researchers operating
outside of clinical settings, for instance in biobanks projects,
may struggle to develop the necessary alliances.
Lack of awareness regarding the possibility of receiving
research results. In most established research projects, the
participants are not aware that genetic results may be provided
to them, as this possibility was not mentioned in the original
informed consent. Collecting the renewed consent of partici-
pants to allow for the feedback process may be burdensome,
expensive, or even impossible for research projects with lim-
ited resources. However, future informed consents are expected
to inform participants about the possibility of feedback, thus
potentially eliminating the need for renewed consent.
Proposed strategies to address challenges
The strategies proposed by the COST Action members to
address the challenges described above are listed below and
summarized in Table 1.
Clarify legal requirements for the feedback of results. The
current legal situation is ambiguous for both researchers and
participants. However, any pursuit of legally binding access
rights to research results ought to also pay attention to
practical and economical obstacles. Researchers should be
encouraged to have clear policies regarding whether or not
they report back the results, and in the former case, what
would be the process for validation of results, counseling,
and care. Further international legal harmonization in this
area should be sought.
Elaborate harmonized European best practices. European
researchers, research funders, research and healthcare in-
stitutions, medical societies, and community representatives
should collaborate at a European level to develop harmo-
nized European best practices for the feedback of genetic
research results to research participants. These discussions
should take into consideration the specific needs, contexts,
laws, and cultural norms of European research. Recent
recommendations for the management of genetic results in
research settings (listed in Table 2)7,35–47 and clinical set-
tings5,6 may be used to guide such work.
Allocate specific funding to the feedback process. Funding
schemes should include specific funding that can be granted
to researchers and healthcare services that establish collab-
oration to provide results to participants. The expected cost
Table 2. Main Recommendations and Guidelines for the Feedback
of Genetic Research Results to Research Participants
Origin Recommendations/guidelines
Canada (LDP) An implementation framework for the feedback of individual research results and
incidental findings in research38
Canada (P3G) Return of research results and incidental findings policy statement41
Canada (RMGA) Statement of principles on the return of research results and incidental findings40
Norway (NBAB) Proposal for a guideline for the use of genome sequencing and genome data in clinical
and research settings35
The Netherlands Feedback of individual genetic results to research participants: in favor of a qualified
disclosure policy43
United Kingdom
(MRC and Wellcome Trust)
Framework on the feedback of health-related findings in research37
United Kingdom (UK10K) Managing clinically significant findings in research: the UK10K example7
United Kingdom (PHG
Foundation)
Managing incidental and pertinent findings from WGS in the 100,000 Genomes Project36
USA Managing incidental findings and research results in genomic research involving
biobanks and archived data sets42
USA (CSER and eMERGE) Return of genomic results to research participants: the floor, the ceiling, and the choices
in between39
USA (NHLBI) Ethical and practical guidelines for reporting genetic research results to study
participants: updated guidelines from a National Heart, Lung, and Blood Institute44
USA (Presidential Commission
for the Study of Bioethical
Issues)
Anticipate and communicate: Ethical management of incidental and secondary findings
in the clinical, research, and Direct-to-Consumer contexts47
Origin Recommendations/guidelines for pediatric research
Canada (P3G) Return of whole-genome sequencing results in pediatric research: a statement of the P3G
international pediatrics platform45
Canada (ICOB) Guidelines for return of research results from pediatric genomic studies: deliberations of
the Boston Children’s Hospital Gene Partnership Informed Cohort Oversight Board46
CSER, Clinical Sequencing Exploratory Research; eMERGE, Electronic Medical Records and Genomics Network; ICOB, Informed
Cohort Oversight Board; LDP, Liver Disease Project; MRC, Medical Research Council; NBAB, Norwegian Biotechnology Advisory
Board; NHLBI, National Heart, Lung, and Blood Institute; PHG Foundation, Foundation for Genomics and Population Health; P3G, Public
Population Project in Genomics and Society; RMGA, Network of Applied Genetic Medicine.
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of the feedback process should be determined as early as
possible in research projects and specified in research ap-
plications.2
Document the health benefits of genetic research results. Pro-
viding genetic research results to research participants may en-
able clinicians to establish more precise diagnoses and prevent
serious conditions. It may also help research participants inform
their own health decisions. Documenting the health benefits of
genetic research results may convince funders, policy makers,
and decision makers to take the necessary legal, financial, and
organizational steps to support the feedback process.
Involve research ethics committees in the feedback process.
Research ethics committees should carefully consider the
feedback process before research is commenced and evaluate
to what extent and how results may be provided to research
participants. These committees may also develop an ethical
framework for determining the researchers’ responsibilities
for feedback of results and reviewing the appropriateness of
researchers’ plans for communicating results.
Enhance the feedback process through interdisciplinary and
cross-institutional collaboration. Expert networks of clinicians,
molecular biologists, bioinformaticians, and geneticists
should be established in research projects to facilitate the
feedback process. If necessary, alliances may be developed
with commercial actors for the supply of specific services
(e.g., laboratory services), which are not available to re-
search teams, but are needed to provide results.
Increase counseling expertise. Educational programs should
be developed to enhance genetic knowledge among health-
care professionals such as medical doctors, clinicians, clini-
cal ethicists, psychologists, nutritionists, nurses, biologists,
and laboratory geneticists who are strategically placed in the
community and may potentially contribute to the feedback
process. Such programs could for instance build upon the
common set of core competences in genetics recently pro-
posed by the European Society of Human Genetics.48
Explore cost-efficient solutions and tools. Participants’ pref-
erences regarding the use of interactive and cost-efficient IT-
based tools such as dynamic consent49 and web-based50 and
telephone-based platforms51 for access to genetic results should
be explored. Cognitive computing for the translation of genetic
results into information of clinical utility52 may also be con-
sidered. This includes research to investigate ethical and legal
requirements pertaining to the use of such platforms.
Increase research participants’ and the general public’s
awareness regarding the feedback of results. Promoting citi-
zens’ participation in science is central to the European
scientific reform.53 Researchers should develop mechanisms
to discuss with citizens and research participants the mo-
dalities of the feedback of results, for instance through
public consultations, debates, and social networks. While it
may often not be feasible to provide individual level results,
the overall results of the study could be meaningful for
people and provided as an acknowledgement that their
participation and contribution are important.
Discussion
The perspective of European researchers and scholars who
are members of the COST Action CHIP ME is that providing
genetic research results to research participants in Europe is,
at present, hardly feasible due to numerous legal, financial,
organizational, and societal challenges. Our study results
corroborate observations made by respondents to a recent
European public consultation who emphasized that providing
genetic results to research participants may be difficult in the
absence of agreement on best practices, clarity regarding
which results to provide, standards for validation of research
results, and allocated funding.54 Similar observations have
been made in clinical genetics settings where the feedback
process is often reported to be practically unfeasible due to
legal, psychological, and organizational issues.55 Logistical
issues may also be encountered when results are available,
but the research participants who should receive the results
cannot be found, such as when personal identifiers are re-
moved to protect the participants’ privacy, which is a com-
mon practice in biobank research.38
To help overcome these challenges, the COST Action
members believe that the proposed recommendations would
help develop a unified strategy to support a pan-European
approach to the feedback of results. These recommendations
are founded on important intercountry commonalities that
emerged in our research. First, challenges to the feedback
process are strikingly similar across European countries;
addressing these challenges collaboratively may therefore
reduce duplication of efforts and reinforce cross-border re-
search collaboration. Second, European countries are com-
mitted to provide, to the extent of their available resources
and capacities, equitable access to healthcare of appropriate
quality.27 If, as most COST Action members believe, re-
search participants’ access to genetic research results that
are clinically significant and actionable can contribute to
better prevention and healthcare, such access should be
made equal and fair across research projects and across
countries. However, this is only possible if legal provisions,
best practices, and organizational structures for the feedback
of results are harmonized throughout Europe. Third, Euro-
pean research is increasingly collaborative, cross-national,
and multicentered. Researchers rely steadily more on Eu-
ropean financial instruments such as the Horizon 2020 of the
EU Research and Innovation programme56for funding. In a
context of strained resources and limited time, it therefore
makes sense to give priority to developing European har-
monized strategies for the feedback of results that can be
applicable in all research projects independent of their
geographical location, rather than national strategies that
may differ dramatically between countries or even require
contradictory action. It should, however, be noted that de-
veloping European harmonized strategies for the feedback
of genetic research results to research participants does not
mean that a single approach to the feedback process must be
adopted throughout Europe. The specificities and varying
contexts of research projects and countries should be taken
into consideration and strategies for the feedback of results
adapted accordingly.
The recommendations proposed by the COST members aim
to address a wide range of considerations spanning legal, fi-
nancial, organizational, and societal issues. Realization of the
ideas comprising these recommendations will require a step-
wise process with some endeavors more readily implementable
than others. For instance, involving research committees in the
design of the feedback process and developing interdisciplinary
and cross-institutional collaboration to support such feedback
does not pose critical barriers; established channels already
exist for engaging the relevant actors and entities. In contrast,
increasing counseling expertise among healthcare professionals,
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documenting the health benefits of genetic research results, and
allocating additional funding to the feedback process require
more extensive efforts, are time-consuming, and may be diffi-
cult to achieve in countries where the financial resources of
healthcare systems are scarce. To help move this agenda for-
ward, it is important to work together as a community to build
consensus and momentum through projects and initiatives that
bring relevant stakeholders together such as this COST action.
Furthermore, we can start to prioritize efforts on those
recommendations that can be implemented rapidly and at a
reasonable cost. As an illustration, work has already been
completed in exploring how the feedback process may be
supported through the use of online tools.57 Some of these
tools are open source and are readily available to research
groups.57 By incorporating information in the informed
consent process about the possibility that genetic results
may be provided in the future and offering research par-
ticipants the opportunity to reflect upon such possibility,
research groups may be able to gradually start providing the
results that are most urgent. Researchers could take a
number of actions such as discussing with their research
ethics committee and cooperating with clinical laboratories
and clinicians in their network to identify the results that
should be given priority. Importantly, researchers urgently
need clarification regarding legal requirements for the
feedback of results and access to practical guidelines out-
lining which type of results should be fed back and how. As
noted above, such guidelines may be developed on the basis
of already existing policies.
A critical consideration going forward is how to best har-
monize such policies between clinical and research milieus.
The current situation in which clinical recommendations5,6
may only be partly transferable to research settings due to
differences in methodologies and quality requirements may
change rapidly as the methodologies and sequencing coverage
used in each setting become more similar. Currently, clinicians
often use high levels of sequencing coverage and focus on
specific sets of genes to produce precise results that can be
used for diagnostic purposes. In contrast, researchers usually
produce, in a single test, data for up to billions of individual
analytes.58 Assessing the analytical performance of genetic
tests, including their specificity, sensitivity, and level of pre-
cision, is challenging when such large amounts of data are
produced.58 Similarly, determining which genetic variants
have clinical utility is difficult as the significance of most
variants detected by researchers is currently unknown, and our
current knowledge of polygenic risk assessment is in nascent
stages, as is our understanding of population differences as-
sociated with the risk of specific variants. Research guidelines
will need to include additional criteria and assessment meth-
ods to certify the quality and accuracy of genetic results pro-
duced through research and provide references to well-
annotated genetic reference databases establishing the patho-
genicity of variants.
With the rapid changes in technologies and the increased
integration of personal genomes and sequencing in health-
care, the divide between research and clinical care may
diminish considerably (or completely disappear) with regard
to the technical differences underlying genomic information
that is generated about a participant versus a patient. This
will add new nuance regarding the differences in the re-
quirements between clinical care and research to provide
results to the individual.
Providing individual research results to participants is
expected to benefit research participants as it enables more
proactive behavior, whereby individuals may be able to seek
qualified medical help and receive appropriate advice or
treatment. However, it is important to consider the risks, as
well as the benefits, of providing results. Research partici-
pants may react differently when learning about their genetic
status: some with anxiety and others with eagerness to act,
for instance by starting treatment or undergoing surgery.
Knowledge about genetic disease or predisposition may also
impact the life of biological relatives and could have sig-
nificance for future family planning.19 It is therefore im-
portant that results are provided in a qualified and transparent
manner, and in accordance with the participants’ wishes, and
that researchers specify the extent to which the results are
accurate and reliable to guide people’s choices and avoid
unnecessary harm and distress.
Implications for European decision makers
Providing individual genetic research results that are
clinically useful and actionable is increasingly seen as an
ethical and legal obligation, and a healthcare necessity.3
Informing research participants about their results makes
sense in today’s world where patients and research partici-
pants are increasingly willing to share their personal health
information,59 including clinical and lifestyle data, with re-
searchers and healthcare providers and also take initiatives to
share their data through web-based portals60 and devices.61
However, relying solely on the good will and initiative of
researchers to provide results to research participants is not
sufficient. European policy makers, funders, and research
and healthcare institutions have a joint responsibility to en-
sure that the necessary prerequisites are in place to enable
research participants to access their genetic research results
of health relevance in an equitable, scientifically sound, and
ethically and socially robust way across Europe. The COST
Action members will continue their efforts to coordinate
activities at the European level to help advance this agenda.
We hope that our research results will contribute to increased
awareness regarding the need to develop mechanisms that
enable biobanks and research groups to fulfill their ethical
obligations toward research participants.
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